Exciting Investigational Therapies in Advanced RCC
The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.
Emerging Data in Non-Clear Cell RCC Treatment
Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.
COSMIC-313: Frontline Triplet Therapy in Advanced RCC
Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.
Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial
Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.
Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment
Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.
Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment
Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.
Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC
Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.
Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC
Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.
Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)
Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.
Dr. Ornstein on Toxicity Concerns for Neoadjuvant Therapy in Localized RCC
Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.
Dr. Ornstein on Unmet Needs in Refractory RCC
Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.
Dr. Ornstein on the Efficacy of Neoadjuvant Avelumab and Axitinib in RCC
Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.
Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC
Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.
Dr. Ornstein on Challenges With Immunotherapy in RCC
Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the challenges surrounding immunotherapy for patients with renal cell carcinoma.
Dr. Ornstein on Role of IL-2 in Patients With RCC
Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).
Preparing for the Unexpected: What You're Not Told During Orientation
As you begin your first year of oncology fellowship, I want to share with you a few things
Iâ€™ve learned since standing in your shoes just 12 months ago.
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
2 Clarke Drive Cranbury, NJ 08512